Breaking News

Morocco’s Hospitals Supplied with Chloroquine Drug as Potential COVID-19 Treatment

Morocco’s Hospitals  Supplied with Chloroquine Drug as Potential COVID-19 Treatment.



After conferences with the scientific committee of the national program for the prevention and control of influenza and acute respiratory infections. Morocco’s Ministry of Health has decided to provide health establishments across the country with chloroquine drug and its derivative, as a novel coronavirus precaution.

The Ministry of Health affirmed that all prescriptions must be made on a normative prescription including all necessary information concerning the dose and instructions for usage.

As a precaution, the Moroccan authorities purchased all the stock of Nivaquine, produced by the Sanofi Laboratories at their factories in Casablanca.


Morocco also applied for an additional quantity of Nivaquine from Sanofi Labs.

Chloroquine also known as chloroquine phosphate is a medication used to prevent and to treat malaria in adults, caused by mosquito bites in countries where malaria is common.Certain sortes of malaria, resistant strains, and complicated cases typically require different or additional medication.Occasionally it is used for amebiasis that is occurring outside the intestines, rheumatoid arthritis, and lupus erythematosus. 

Despite the effectiveness of chloroquine but it can cause many  common side effects include loss of appetite ,muscle problems, , diarrhea, and skin rash, etc. Serious side effects include loss of vision due to retinal toxicity, muscle damage, seizures,etc.

Recent publications have  brought attention to the potential benefit of chloroquine, and about its efficacy to treat patients with new coronavirus (SARS-CoV-2). The scientific community should consider this information in light of advanced experiences with chloroquine in antiviral research.

No comments